Pliant Therapeutics (PLRX) Depreciation & Amortization (CF) (2019 - 2026)
Pliant Therapeutics (PLRX) reported Depreciation & Amortization (CF) of $264000.0 for Q1 2026, down 34.0% year-over-year from $400000.0 in Q1 2025, and down 28.46% quarter-over-quarter from $369000.0 in Q4 2025.
Pliant Therapeutics (PLRX) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has 8 years of Depreciation & Amortization (CF) data on file, last reported at $264000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $264000.0, down 34.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 million (down 25.87% YoY), and the FY2025 annual result was $1.7 million, down 19.05% from the prior year.
- Depreciation & Amortization (CF) slipped to $264000.0 in Q1 2026 per PLRX's latest filing, from $369000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $600000.0 in Q2 2024 and troughed at $264000.0 in Q1 2026.
- A 5-year average of $442411.8 and a median of $432000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2024 and 2026: Depreciation & Amortization (CF) soared 50.0% in 2024, then sank 34.0% in 2026.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $432000.0 in 2022, then decreased by 2.08% to $423000.0 in 2023, then gained by 2.36% to $433000.0 in 2024, then retreated by 14.78% to $369000.0 in 2025, then retreated by 28.46% to $264000.0 in 2026.
- Business Quant data shows PLRX's Depreciation & Amortization (CF) at $264000.0 in Q1 2026, $369000.0 in Q4 2025, and $400000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 429,663.65 |
| 10 | Pliant Therapeutics | 71.07 Mn | 71.07 Mn | - | 264,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 264,000.00 |
| Mar 31, 2026 | 264,000.00 |
| Dec 31, 2025 | 369,000.00 |
| Dec 31, 2025 | 369,000.00 |
| Sep 30, 2025 | 400,000.00 |
| Sep 30, 2025 | 400,000.00 |
| Jun 30, 2025 | 400,000.00 |
| Jun 30, 2025 | 400,000.00 |
| Mar 31, 2025 | 400,000.00 |
| Mar 31, 2025 | 400,000.00 |
| Dec 31, 2024 | 433,000.00 |
| Dec 31, 2024 | 433,000.00 |
| Sep 30, 2024 | 500,000.00 |
| Sep 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 600,000.00 |
| Jun 30, 2024 | 600,000.00 |
| Mar 31, 2024 | 500,000.00 |
| Mar 31, 2024 | 500,000.00 |
| Dec 31, 2023 | 423,000.00 |
| Dec 31, 2023 | 423,000.00 |